Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: Single institutional results

Annals of Oncology

Volumn 16, Issue 12, 2005, Pages 1936-1940

  Alebouyeh, M ^a,b   Moussavi, F ^a   Haddad Deylami, H ^a   Vossough, P ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NONE   (Iran)

Author keywords

Ambulatory treatment; Childhood Hodgkin's; Iran; Late effects; Survival

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ACUTE DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE TOXICITY; ADOLESCENT; ADVANCED CANCER; ARTICLE; AZOOSPERMIA; BLEEDING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IRAN; LYMPHOCYTE DEPLETION; LYMPHOCYTOMA; MALE; MALE INFERTILITY; MEDIASTINUM MASS; MENORRHAGIA; MIXED CELL LYMPHOMA; NONHODGKIN LYMPHOMA; OUTPATIENT CARE; PARAAORTIC LYMPH NODE; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; SALVAGE THERAPY; SCLEROSIS; SECOND CANCER; SPLEEN TUMOR; SURVIVAL RATE; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 28444499347     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi401     Document Type: Article

References (28)

1. Schellong G. Pediatric Hodgkin's disease: Treatment in the late 1990s. Ann Oncol 1998; 9: 115-119.
2. Oberlin O, Leverger G, Pacquement H et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin disease. The experience of the French Society of Pediatric Oncology. J Clin Oncol 1992; 10: 1602-1608.
3. Schellong G. Treatment of children and adolescents with Hodgkin's disease: The experience of the German-Austrian Paediatric Study Group. Bailliere's Clin Haematol 1996; 9: 619-634.
4. Donaldson S. A discourse: The 2002 Wataru W. Sutow Lecture. Hodgkin's disease in children-perspectives and progress. Med Pediatr Oncol 2003; 40: 73-81.
5. Schellong G, Potter R, Bramswig J et al. High cure rates and reduced long term toxicity in pediatric Hodgkin's disease: The German-Austrian Multicenter Trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999; 17: 3736-3744.
6. Alebouyeh M, Haddad-Deylami H, Vossough P. Childhood malignancies in Iran: A suvey based on MAHAK cancer registry. INCTR meeting, Brussels, Belgium 2003 (Abstract 36, INCTR, Institut Pasteur, 1180 Brussels, Belgium).
7. Dionet C, Oberlin O, Habrand JL et al. Initial chemotherapy and low-dose radiation in limited field in childhood Hodgkin's disease: Results of joint cooperative study by the French Socierty of Pediatric Oncology (SFOP) and Hospital Saint-Louis, Paris. Int J Radiat Oncol Biol Phys 1988; 15: 341-346.
8. Dorffel W, Albrecht M, Lueders H et al. Multi-national therapy study for Hodgkin's disease in children and adolescents GPOH-DH 95. Interim report after 2 1/2 years. Klin Padiatr 1998; 210: 212-219.
9. Shankar AG, Ashley S, Radford M et al. Does histology influence outcome in childhood Hodgkin's disease? Results from the United Kingdom Children's Cancer Study Group. J Clin Oncol 1997; 15: 2622-2630.
10. Arya LS, Dinand V, Bakhshi S et al. Significance of splenomegaly in childhood Hodgkin disease. J Pediatr Hematol Oncol 2004; 26: 807-812.
11. Dieckmann K, Potter R, Hofmann J et al. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-1993HD 90. Int J Radiat Oncol Biol Phys 2003; 152: 21-23.
12. Alebouyeh M, Vossough P. Hodgkin disease in Iranian children. Eur J Pediatr 1993; 152: 21-23.
13. van den Berg H, Furstner F, van den Bos C, Behrendt H. Decreasing the number of MOPP course reduces gonadal damages in survivors of childhood Hodgkin disease. Pediatr Blood Cancer 2004; 42: 210-215.
14. Le Deley MC, Leblanc T, Shamsaldin A et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracycline: Case-control study by Societe Francaisee d'Oncologie Pediatrique. J Clin Oncol 2003; 21: 1074-1081.
15. Hobbie WL, Ginsberg JP, Ogle SK et al. Fertility in males treated for Hodgkin's disease with COPP/ABV hybrid. Pediatr Blood Cancer 2005; 44: 193-196.
16. Horholz D, Claviez A, Hasenclever D et al. The Concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: Evolution in the tradition of the DAL/GPOH studies. Klin Padiatr 2004; 216: 150-156.
17. Brougham MF, Kelnar CJ, Sharpe RM, Wallace WH. Male fertility following childhood cancer: Current concepts and future therapies. Asian J Androl 2003; 5: 325-337.
18. Kaicker S, Kelly K. Pediatric Hodgkin's disease: Current concepts in diagnosis and management. Indian Pediatr 2000; 37: 933-938.
19. Dorffel W, Luders H, Ruhl U et al. Preliminary results of the multi- center trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: Analysis and outlook. Klin Padiatr 2003; 215: 139-145.
20. Lobo Sanahuja F, Garcia I, Bararantes JC et al. Pediatric Hodgkin's disease in Costa Rica: Twelve years experience of primary treatment by chemotherapy alone, without staging laparotomy. Med Pediatr Oncol 1994; 22: 398-403.
21. Baez F, Ocampo E, Conter V et al. Treatment of childhood Hodgkin's disease with COPP or COPP/ABV (hybrid) without radiotherapy in Nicaragua. Ann Oncol 1997; 8: 215-216.
22. Sagar TG, Chandra A, Raman SG. Childhood Hodgkin disease treated with COPP/ABV hybrid chemotherapy: A progress report. Med Pediatr Oncol 2003; 40: 66-69.
23. Hakvoort-Camme FGAJ, Buitendijk S, van den Heuvel-Eibrink M, Hahlen K. Treatment of pediatric Hodgkin disease avoiding radiotherapy: Excellent outcome with the Rotterdam-HD-84-Protocol. Pediatr Blood Cancer 2004; 43: 8-16.
24. Sankila R, Garwicz S, Olsen JH et al. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: A population-based cohort study in the five Nordic countries. J Clin Oncol 1996; 14: 1442-1446.
25. Metayer C, Lynch CF, Clarke EA et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 2000; 18: 2435-2443.
26. Bhatia S, Yasui Y, Robison LL et al. High risk of subsequent neoplasms continue with extended follow-up of childhood Hodgkin's disease: Report from the Late Effects Study Group. J Clin Oncol 2003; 21: 4386-4394.
27. Ragusa R, Russo S, Villari L, Schiliro G. Hodgkin's disease as a second malignant neoplasm in childhood: Report of a case and review of the literature. Pediatr Hematol Oncol 2001; 18: 407-414.
28. Alebouyeh M. Pediatric hematology and oncology in Iran. Pediatr Hematol Oncol 2005; 22: 1-9.